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Imaging of conditional gene 
silencing in vivo using a 
bioluminescence-based method 
with thermo-inducible microRNAs
Karine Pinel1,2, Coralie Genevois  1, Christelle Debeissat1 & Franck Couillaud  1
RNA interference (RNAi)-based gene therapy has great potential in cancer and infectious disease 
treatment to correct abnormal up-regulation of gene expression. We show a new original method uses 
synthetic microRNAs combined with a thermo-inducible promoter to reduce specific gene expression. 
The targeted gene is the luciferase firefly reporter gene overexpressed in a subcutaneous tumor which 
allows the RNAi monitoring by bioluminescence imaging (BLI). The inducible inhibition was first 
demonstrated in vitro using genetically modified cells lines and then in vivo using the corresponding 
xenograft model in mice. Achieving spatio-temporal control, we demonstrate the feasibility to induce, 
in vivo, a specific gene inhibition on demand. Future applications of this RNAi-based gene therapy, 
which can be restricted to pathological tissue, would offer wide-ranging potential for disease treatment.
RNA interference (RNAi) is an evolutionarily-conserved mechanism which has become a revolutionary strategy 
to regulate gene expression. This biological process, mediated by small interfering RNAs (siRNAs), short hairpin 
RNAs (shRNAs) or microRNAs (miRNAs), has rapidly emerged as a key experimental tool for gene function 
analysis and target validation in mammalian systems, both in vitro and in vivo. As a consequence, RNAi appears 
to be an attractive technology for gene therapy to down-regulate specific genes1. However, RNAi induction 
mediated by siRNAs is limited by their pharmacokinetic properties, their poor cell penetration and their limited 
activity in vivo2. Similarly, although not a prerequisite, experimental studies often use polymerase III-dependent 
promoters for applications that require shRNA synthesis. The development of shRNA embedded in a miRNA 
scaffold driven by RNA polymerase II makes tissue-specific or inducible RNAi possible by using a wide variety of 
promoters. Furthermore, biosynthesis of optimized shRNAs based on miRNA cell processing machinery provide 
efficient and safe therapeutic routes for RNAi induction in vitro and in vivo3–5. MiRNAs are a class of non-coding 
RNA implicated in the regulation of around 30% of the cell transcriptome6. MiRNAs can naturally direct gene 
silencing at a post-transcriptional level. Most gene therapies require restriction of the treatment to the targeted 
tissues to minimize unwanted side effects. Thus, RNAi-based therapies require spatial control of the induction. 
Heat-sensitive transgene expression systems have been proposed for use in gene therapy to enable spatial control 
of gene activity, also offering temporal control. HSP (heat shock protein)-related promoters are inducible and 
external heat treatment enables their activation. In vitro feasibility of the transcription of an artificial miRNA by 
HSP-related promoters has been reported7 but only following transient cell transfection. However, the Hsp70B 
promoter has many advantages including its low basal activity and the heat-induced expression8–11 which could 
create new approaches for Hsp-controlled RNAi systems in vivo. Moreover, the efficient control of gene expres-
sion in vivo using a HSP-related promoter has been reported using encoding genes such as HSV thymidine kinase, 
FAS ligand and cytokine genes9,12–14 or reporter genes for in vivo monitoring10,15,16.
In this study, we propose a new in vivo method to combine the shRNA embedded in a miRNA scaffold inhib-
itory effect with its thermo-induced expression driven by the Hsp70B promoter. This article demonstrates the 
feasibility and efficiency of this strategy in vitro followed by its implementation in vivo using the reporter gene 
firefly luciferase (LucF) as the target gene.
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Material and Methods
Animals. Animal manipulations were performed in agreement with both European and French directives. 
The present project was approved by the local ethical committee (CEEA 50) under agreement A50120194. Female 
immunodeficient NOG (NOD/SCID/IL-2Rγnull) mice (6- to 10-weeks-old) were purchased and reared at the 
University of Bordeaux animal facilities. Animals were maintained in standard conditions under a 12 hour light/
dark cycle with water and food provided ad libitum. Animals were anesthetized with 2% isoflurane (Belamont, 
Nicholas Piramal Limited, London, GB) in air. The posterior region of the mice was shaved with clippers and a 
depilatory cream on the day before imaging.
DNA constructs. Plasmids pcDNA6.2-GW EmGFP-miRLuc and pcDNA6.2-GW EmGFP-miRneg were pur-
chased from Invitrogen (BLOCK-iTTM system, Life TechnologiesTM, Carlsbad, CA, USA). These vectors allowed 
for co-cistronic expression of the EmGFP (Emerald Green Fluorescent Protein) reporter gene and synthetic 
miRNA under the transcriptional control of the constitutive CMV promoter. Correlation between EmGFP and 
miRNA expressions was previously demonstrated (Life TechnologiesTM). The pcDNA6.2-GW EmGFP-miRLuc 
encoded a mature synthetic miRLuc specific to the LucF mRNA. pcDNA6.2-GW EmGFP-miRneg encoded a 
mature miRNA called miRneg, unrelated to any known gene and used as a negative control. To increase efficiency 
of the inhibitory effect of miRNA, 3 additional copies of each pre-miRNA were cloned into the pcDNA6.2-GW 
EmGFP-miRLuc and pcDNA6.2-GW EmGFP-miRneg vectors to obtain the pcDNA6.2-GW EmGFP-4*miRLuc 
and pcDNA6.2-GW EmGFP-4*miRneg plasmids.
The Hsp70B promoter sequence was excised from pD3SX vector (Stressgen Biotechnologies Corp. Victoria, 
BC, Canada). Renilla luciferase (LucR) reporter gene was excised from pRL-CMV vector (Promega). By several 
cloning steps the CMV promoter from pcDNA6.2-GW EmGFP-4*miRLuc and pcDNA6.2-GW EmGFP-4*miRneg 
was replaced by a Hsp-LucR-Hsp cassette to obtain pcDNA6.2-Hsp-LucR-Hsp-EmGFP-4*miRLuc and pcD-
NA6.2-Hsp-LucR-Hsp-EmGFP-4*miRneg constructs.
Cell culture and stable transfections. The different U87 cells lines were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM; Life TechnologiesTM) supplemented with 10% fetal calf serum (Life 
TechnologiesTM), 1% antimycotic-antibiotic mix (PSA; Life TechnologiesTM) and 1% non-essential amino-acid 
(MEM NEAA; Life TechnologiesTM) at 37 °C and 5% CO2. Cells were subcultured 1:3 by trypsinization upon 
reaching 90% confluence. The stably transformed U87 CMV-LucF cell17 was further transformed by either pcD-
NA6.2-Hsp-LucR-Hsp-EmGFP-4*miRLuc or pcDNA6.2-Hsp-LucR-Hsp-EmGFP-4*miRneg using TransFastTM 
transfection reagent (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Stably trans-
formed cells lines miRLuc and miRneg were selected with 2 µg/mL blasticidin (PAA, Piscataway, NJ, USA) and 
amplified for both in vitro experiments and tumor generation in NOG mice.
In vitro luciferase assays. Firefly and Renilla luciferases enzymatic activities were measured on cells lysates 
(25,000 cells) using the Dual-Luciferase® Reporter Assay System (Promega) using a luminometer (LUMAT 9501; 
Berthold Technology, Bad Wildbad, DE). Light production was expressed in Relative Light Units (RLU).
RNA isolation, reverse transcription and real-time quantitative polymerase chain reac-
tion. RNA isolation. Total RNA and miRNA were extracted from tumors (40 mg) and cells with the miRNe-
asy Mini kit (Qiagen, Hilden, DE) according to the manufacturer’s instructions. During extraction, DNase digest 
is performed (RNase-Free DNase set; Qiagen). Total RNA was quantified using Quanti-iT™ RiboGreen RNA Kit 
(Invitrogen, Molecular probes) on a fluorimeter (Versafluor®; Bio-RAD).
Reporter gene qRT-PCR. Reverse transcription was performed on 1 µg total RNA using ImProm-II™ Reverse 
Transcription System (Promega, Madison, WI, USA) and random hexameric primers (Promega). Real time 
PCR reactions were performed with SYBR® Green I dye (Thermo Scientific, St. Leon-Rot, DE) on MyIQ Real 
Time thermocycler (Bio-RAD, Hercules, California, USA) according to manufacturer’s protocol and primers 
(Supplementary Table S1) (Eurogentec; Seraing, BE). Normalization was performed regarding to 36B4 gene level 
and the relative expression for a target gene was calculated using the comparative Ct method (2−ΔΔCt).
miRNA qRT-PCR. Stem-loop reverse transcription reaction is performed on total RNA (1 µg) using Multiscribe 
RT enzyme (TaqMan® MicroRNA Reverse Transcription kit; Life TechnologiesTM) according to manufacturer’s 
protocol and using the stem–loop RT primer (Eurogentec) (Supplementary Table S2). Real time PCR reactions 
were performed using SYBR®Geen I dye and specific primers (Supplementary Table S3). The expression level of 
miRNA was normalized to the small nucleolar RNA RNU44 and the relative expression was calculated using the 
comparative Ct method (2−ΔΔCt).
Flow cytometry. Cells were trypsinized and washed in PBS. Each cell suspension in PBS was analyzed by 
flow cytometry to determine the level of EmGFP expression using a Guava easycyteTM Flow Cytometer (Merck 
Millipore, Darmstadt, DE). For each analysis, 10,000 events were captured. Dual blue (488 nm excitation wave-
length) excitation laser and green fluorescent channel (525/30 nm) were used to quantify the number of positives 
cells. The flow cytometry data was analyzed with the Incyte software.
Subcutaneous tumor generation. U87 cell suspension (2 × 106 cells; 100 µL PBS) was inoculated into 
the subcutaneous tissue in the mice using an U-100 insulin syringe (TERUMO®, Cottontail Lane Somerset, NJ, 
USA). MiRLuc and miRneg cell lines were injected into hind legs. For this, one tumor per animal was gen-
erated, using the left side for the miRLuc cell line and the right side for the miRneg cell line. Once the tumor 
became palpable, tumor width and length were measured using a digital caliper by the same researcher to prevent 
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observation differences, during all the time-course. The tumor volume was then calculated using the Feldman et 
al. formula18: Volume = π/6 ∙ f ∙ (length ∙ width)3/2.
Hyperthermia treatment. Cell hyperthermia. Cells were plated 48 hours before the experiment (15,000 
cells per well into 4-well plates). Hyperthermia was induced using a water bath (45 °C; 20 min) and the media was 
renewed using pre-warmed media, then the cells were returned to the incubator at 37 °C and 5% CO2.
Tumor hyperthermia. When tumors reached a volume of 110 ± 80 mm3, anesthetized mice were placed on a 
polystyrene-isolated platform floating on the surface of a water-bath. Mice hind legs were dipped into hot water 
(45 °C +/− 0.1 °C; 8 min) by a hole in the platform, thus heating only the legs while the rest of the body was lying 
on the isolation material.
In vivo bioluminescence imaging. BLI was performed at VivOptic (UMS 3767, Bordeaux University, FR) 
using a Lumina LT system (Perkin Elmer Inc., Boston, MA, USA) including a highly sensitive CCD camera. For 
LucF signal detection, mice received an intra-peritoneal injection of D-luciferin (Promega, Madison, WI, USA, 
2.9 mg in 100 µL PBS) and were sedated 7 min later. For LucR signal detection, mice received an intra-peritoneal 
injection of ViviRen (Promega, 50.8 µg in 100 µL PBS-BSA 0.1%) and were sedated 17 min later. Bioluminescence 
images (1 min, 4 × 4 binning) and photographs (100 ms exposure) were taken at 10 min or 20 min after the sub-
strate injection for LucF and LucR respectively. The bioluminescence signal was converted using a false color scale 
and images representing the spatial distribution of emitted photons were generated using Living Image software 
(Perkin Elmer Inc.) and superimposed on to the photograph. BLI analysis was performed semi-automatically 
by placing a small region of interest (ROI) on the leg. The mean light intensity (in photons.s−1.mm−2.sr−1) was 
measured within this ROI.
Statistical analyses. All statistical analyses were performed using a two-tailed unpaired Student’s t test for 
comparison of two groups and a statistical difference was considered as *P < 0.05, **P < 0.01 and ***P < 0.001. 
In the qRT-PCR experiment, the statistical analyses were made on the dCt for more accuracy. All data were rep-
resented as mean ± s.e.m.
Results and Discussion
A thermo-inducible inhibition strategy through the Hsp70B promoter. To demonstrate the feasi-
bility of our method, we generated cell lines which constitutively express the LucF reporter gene (CMV promoter) 
and contained inducible Renilla luciferase (LucR), emerald GFP (EmGFP) and 4 copies of synthetic miRNAs under 
the Hsp70B transcriptional control (Fig. 1A). This strategy aimed to control the heat-induction using LucR and 
EmGFP as reporters and monitoring the effect of the miRNA on the LucF expression in vivo. Furthermore, the 
separate monitoring of LucF and LucR expressions allowed the distinction between heat-induction and the effect 
of the synthetic miRNA as these luciferases have their own substrate and show distinct kinetics of light produc-
tion in vivo. RNAi was assessed by specific synthetic miRNAs (miRLuc) targeting LucF mRNA (Supplementary 
Figure S4) and miRneg (unrelated to any known gene) was used as a negative control. After in vitro validation, 
we generated subcutaneous tumors in mice to follow heat-induced target gene inhibition by bioluminescence 
imaging (BLI), involving the non-invasive interrogation of living animals using light emitted from luciferase-ex-
pressing cells.
Thermo-induced RNAi in vitro. In vitro, after a heat shock of the miRLuc and miRneg cell lines, the syn-
thetic miRNAs expressions showed an increase of miRLuc and miRneg miRNAs levels 6 hours after treatment 
(Fig. 1B). To control the Hsp70B promoter activation after a short and transient heat shock of miRLuc and miR-
neg cell lines, LucR and EmGFP expression were followed using enzymatic assays and flow cytometry respectively 
(Fig. 1C and D respectively). Our data shows low basal activity for LucR and EmGFP. A maximal level of activa-
tion was reached 6 hours after hyperthermia for the two reporter proteins in both cells lines, thus suggesting an 
early activation of Hsp70B promoters in accordance with the literature. Interestingly Fig. 1D showed a difference 
in EmGFP kinetics between cell lines which prompted us to not use this reporter as an internal control for the 
subsequent experiments. Additionally, we measured the endogenous Hsp70 pathway which showed a transient 
induction of Hsp70 mRNAs expression (transcripts resulting from the transcription driven by all the Hsp70 pro-
moters) (Supplementary Figure S5). Although Hsp70B promoter was described to exhibit a relatively low basal 
activity, as shown in Fig. 1, our data demonstrated the efficiency of the Hsp70B-induced promoter activation by 
hyperthermia in vitro. This allowed us to pursue further investigations on miRLuc efficiency. We investigated 
whether miRLuc impacted on LucF mRNA content and LucF activity in the miRLuc cell line (Fig. 2A and B 
respectively, both normalized to miRneg cell line). Our results showed a 50% decrease in LucF mRNA content 
expression 6 hours following hyperthermic miRLuc expression induction by hyperthermia which was sustained 
for 24 hours before returning to normal levels two days post-treatment (Fig. 2A). This result showed the efficiency 
of the synthetic miRNA on the degradation of its mRNA target. Furthermore, outcomes of this repression were 
delayed in time for LucF activity. LucF activity showed a minimum 50% decrease one to two days following 
miRLuc induction by heat treatment (Fig. 2B). Overall, in vitro experiments validated the thermo-induced RNAi 
strategy.
In vivo gene inhibition via Hsp70B-induced miRNA expression. To generate xenograft tumors, 
miRLuc and miRneg cell lines were injected subcutaneously in immunodeficient mice legs. The constitutive 
expression of LucF enabled tumor growth monitoring by BLI. In vivo hyperthermia was performed by bathing 
mice legs in a water-bath (45 °C; 8 min). LucR expression was then monitored to control hyperthermia efficiency 
(Fig. 3A). In accordance with our in vitro observation, the LucR bioluminescent signal was detected 6 hours after 
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hyperthermia in both tumors. Synthetic miRNA contents and Hsp mRNA were quantified by qRT-PCR in tumor 
samples at different time points after hyperthermia (Fig. 3B and Supplementary Figure S6 respectively). The pro-
file obtained for Hsp mRNA expression after hyperthermia in vivo was transient with a maximum at 6 hours as 
observed in vitro (Supplementary Figure S5) for the two cell lines. Furthermore, our data showed the induction 
of the synthetic miRNAs expression in vivo. These results confirmed the suitability of our heating method to 
induce Hsp70B promoters in vivo. Previous studies by others in mammalian cells showed a half-life of LucF of 3 
hours19,20 and we previously measured a half-life of around 20 hours in an in vivo mouse model21. It is important 
to note that this half-life enables the measurement of any dynamic changes in LucF reporter transcription level 
in vivo. Subsequently, the effectiveness of miRLuc to reduce LucF expression was investigated by BLI monitoring. 
The time courses of LucF activity as well as the measurement of tumor growth were followed on both miRLuc 
and miRneg tumors from day one (beginning of the effect observed in vitro; Fig. 2B) to two days after hyperther-
mia. The BLI/tumor size ratio between the different time points after hyperthermia was calculated for miRneg 
and miRLuc tumors (Fig. 4). Our data shows a significantly higher reduction of the BLI/tumor ratio for the 
Figure 1. In vitro heat-shock efficiency. (A) Diagram of the constructs. (B) Relative quantification (RQ) of 
miRNAs in heat-shock induced (45 °C; 20 min) miRneg and miRluc cell lines respectively (n = 3) (Student’s 
t-test; *p < 0.05 and **p < 0.01: vs. 0 h). (C) Measurement of the LucR activity by in vitro enzymatic assay with 
a maximum at 6 h post-hyperthermia in both miRLuc and miRneg cell lines (n = 3) (Student’s t-test, **p < 0.01 
and ***p < 0.001: vs. 0 h). (D) Mean fluorescence intensity (MFI) of EmGFP determined by flow cytometry 
with a maximum at 6 h post-hyperthermia in both miRLuc and miRneg cell lines (n = 3) (Student’s t-test, 
**p < 0.01 and ***p < 0.001: vs. 0 h).
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miRLuc tumor compared to miRneg after hyperthermia. This result corroborated our first in vitro observations 
and showed, in vivo, the efficiency of the heat-induced miRNA on its target gene.
Conclusion
This study describes the utilization of a Hsp-controlled RNAi system in which a conditional synthetic miRNA 
was specifically designed to silence a reporter gene in vivo. We demonstrated the feasibility of on demand 
heat-triggered gene inhibition to ensure spatio-temporal control of gene inhibition in vivo. This method repre-
sents a new strategy that experts from different fields could use to address biological questions from their specific 
topics. For example, in the cancer field, it is well established that cell transformation is caused by multiple gene 
dysregulation (e.g. oncogenes). In such a pathological context, this new method could demonstrate its appli-
cability to cancer treatment by targeting specific oncogenes in patient tumors. Indeed, we showed that several 
Hsp-driven transgenic expressions could be induced simultaneously including a mix of genes (two in the present 
work) and miRNAs (currently 4 copies) providing a way for multiple targeted regulation. But to achieve this goal, 
strategies will have to be developed to efficiently and specifically deliver to the tumor such synthetic miRNAs. 
The transient nature of our new method associated with engineered viruses or naked acid nucleic approaches 
may be promising to achieve gene inhibition while minimizing systemic toxicity. Finally, for this method, the 
activation of the Hsp70B promoter in vivo was accomplished using a water-bath which conferred the advantage of 
being a simple and low-cost system to induce hyperthermia on the entire tumor. More clinically relevant heating 
Figure 2. Thermo-inducible inhibition of LucF reporter gene in vitro. (A) Relative quantification (RQ) of LucF 
mRNA in miRLuc cell line normalized to miRneg cell line for each time point. The graph represents the RQ 
compared to 0 h time point (n = 3) (Student’s t-test; *p < 0.05: vs. 0 h). (B) LucF activity determined by in vitro 
enzymatic assay at different time points after hyperthermia. Values were normalized to miRneg cell line for each 
time point. The graph represents the percentage of LucF activity compared to 0 h time point (n = 3) (Student’s 
t-test; ***p < 0.001: vs. 0 h).
Figure 3. In vivo heat-shock efficiency. (A) Subcutaneous xenografts were generated by the injection of miRLuc 
or miRneg cell lines in mice hind legs. Representative image of LucR signal detection for miRLuc and miRneg 
tumor following intra-peritoneal injection of ViviRen. (B) Relative quantification (RQ) of miRLuc and miRneg 
from miLuc and miRneg tumors respectively determined by qRT-PCR at different time after hyperthermia 
(n = 3) (Student’s t-test, *p < 0.05, **p < 0.01 and ***p < 0.001: vs. 0 h).
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sources such as focal magnetic resonance-guided high-intensity focused ultrasound10,16 could be adapted to the 
Hsp-controlled RNAi system to reach deep tissues and to have a more precise spatial control.
The method demonstrated in this study offers multiple opportunities in terms of application, while also pro-
posing a useful tool to measure efficiency of the inhibitory action of specific miRNA(s) on tumor cell proliferation 
monitored by BLI.
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Figure 4. In vivo monitoring of thermo-induced silencing. Subcutaneous xenografts were generated by the 
injection of miRLuc or miRneg cell lines in mice hind legs. The BLI of LucF activity was measured in heat-
induced miRLuc and miRneg tumors. The graph represents the BLI/tumor size ratio after hyperthermia 
corrected to before heat induction (n = 9 per group) (Student’s t-test between the two groups on the area under 
the curve, *p < 0.05).
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